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Abstract
Background: In a prospective study, long term upper-limb morbidity, perceived disabilities in activities of daily life (ADL) and quality of life
(QOL) were assessed before and 2 years after sentinel lymph node biopsy (SLNB) or axillary lymph node dissections (ALND) for breast
cancer.
Methods: Two hundred and four patients with stage I/II breast cancer, mean age 55.6 years (SD: 11.6) entered the study and 181 patients
(89%) could be evaluated after 2 years. Fifty-seven patients underwent SLNB (31%) and 124 patients underwent an ALND (69%).
Assessments included pain, shoulder range of motion, muscle strength, arm volume, perceived shoulder disability in ADL and QOL.
Results: Significant (P!0.05) changes between before and 2 years after surgery were found in almost all assessments of shoulder function,
ADL and several QOL subscales. Patients in the ALND group showed significant more changes in range of motion (ROM), grip strength, arm
volume, ADL and QOL physical- and role functioning, pain and sleeplessness and arm symptoms compared to the SLNB group. Multivariate
linear regression analysis showed that ALND could predict decrease of ROM, grip strength, ADL and physical functioning (QOL) and
increase of arm volume, pain and arm symptoms score (QOL). Radiation on the axilla predicts an additional decrease in shoulder ROM and
increase of arm volume.
Conclusion: Two years after surgery for breast cancer, patients show significantly less treatment related upper limb morbidity, perceived
disability in ADL and worsening of QOL after SLNB compared with ALND.
q 2005 Elsevier Ltd. All rights reserved.
Keywords: Breast cancer; Sentinel lymph node; Radiation; Morbidity; Quality of lifeIntroduction
The aim of modern breast cancer treatment is to obtain
local tumour control, optimal lymph node staging with
minimal treatment related morbidity and when possible
preservation of the breast. Due to breast cancer screening
programs and multimodality breast cancer treatment the0748-7983/$ - see front matter q 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejso.2005.11.008
* Corresponding author. Address: Department of Rehabilitation Medi-
cine, Martini Hospital Groningen, P.O. Box 30033, NL-9700 RM
Groningen, The Netherlands. Tel.: C31 50 5245885/5245886; fax: C31
50 5245183.
E-mail address: j.s.rietman@planet.nl (J.S. Rietman).number of patients cured after breast cancer is still
increasing as do the 5 and 10 year survival.1,2
Axillary lymph node status is an important prognostic
factor in patients with breast cancer.3–5 Axillary lymph node
dissection (ALND) still is associated with upper limb
morbidity.6 The impact of upper limb morbidity on
disabilities in ADL and QOL in breast cancer patients has
rarely been studied with modern assessment instruments.6–8
Sentinel lymph node biopsy (SLNB) was introduced for
staging of the axilla to reduce the number of unnecessary
ALND’s.9 SLNB is an accurate and safe procedure to
predict metastatic disease in clinically negative axillary
lymph nodes.9–11 An increasing number of studies reportedEJSO 32 (2006) 148–152 www.ejso.com
Table 1




Change (meanGSD) P value
Pain (VAS: 0–10) 0.4G1.1 0.3G1.7 0.01
Numbness (n)a 0 (0%) 114 !0.001
Forward flexion (8) 172.4G11.9 K4.4G12.6 !0.001











Grip strength (Nm) 297.8G64.0 K33.6G51.7 !0.001
Volume arm (ml) 2162G414 124G241 !0.001
SDQ (0–100) 8.2G19.7 10.5G29.9 !0.001
GARS (18–72) 19.6G3.7 1.8G5.7 !0.001
(8), grades; Nm, Newton meter; ml, millilitre; SD, standard deviation; SDQ,
the shoulder disability questionnaire32; GARS, the Groningen activity
restriction scale.33,34
a No standard deviations were given because it concerns a dichotomous
variable.
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ALND.12–20 Generally disability in ADL of the SLNB
group was less than that of the ALND group.13,16,19
A shortcoming in most studies is the absence of pre-
treatment assessment and the absent of reliable and
validated assessment instruments. Although association
between upper limb morbidity and poorer QOL was
described, QOL is seldom considered in the debate on
axillary surgery.6,8,20–22
The aim of the current prospective study was to analyse
long-term upper limb morbidity, perceived disability in
ADL and QOL 2 years after SLNB or ALND. The second
aim was to analyse to which extent ALND and other
treatment variables could predict upper limb morbidity,
perceived disability and decreased QOL.
Patients and methods
From June 1999 to June 2001, patients with breast
carcinoma stage I or stage II entered the study.23 Patients
were retrieved from the Groningen University Medical
Centre and the Martini Hospital Groningen. Informed
consent was obtained from the participating patients. The
protocol was approved by the Institutional Review Board of
both hospitals. Two groups of breast cancer patients
participated in the prospective study, patients who under-
went conventional breast cancer treatment with an ALND
and patients who were treated according the SLNB concept.
Sentinel lymph nodes were identified by pre-operative
lymphoscintigraphy followed by intraoperative tracing
using a gamma probe and Patent blue dyew (Blue Patente´;
Labatoire Guerbet, Aulnay-sous-Bois, France). The pro-
cedure has been previously described in detail.24 If
pathological examination revealed metastases in the
sentinel lymph node, ALND was performed within two
weeks after SLNB.
Pain (VAS25), upper limb function (range of motion,
muscle strength, arm volume),26–31 numbness, ADL32–34
and QOL35,36 were assessed 1 day before surgery (t0) and 2
years after surgery (t1) (Table 1). The shoulder disability
questionnaire (SDQ) was designed to evaluate the ability to
perform daily activities in patients with shoulder dis-
orders.32,37,38 The Groningen activity restriction scale
(GARS) assesses the perceived restrictions (disability) in
performing 18 ADLs.33,34 A higher score represents more
functional status limitation.
Quality of life was assessed with help of the EORTC
QLQ-C30 questionnaire supplemented with the EORTC
breast module (EORTC QLQ-BR23).35,36
Statistical analyses included descriptive statistics and
t-tests for independent samples for between-group compari-
sons and t-tests for dependent samples for within-group
comparisons. Pearson’s chi-squared test was used for
dichotomous variables. To answer the question in which
extent treatment variables could predict upper limb
morbidity, perceived disability and poorer QOL,multivariate linear regression analyses were performed.
Differences were accepted as significant if P values were !
0.05. SPSSw Base 11.5 software for Windowsw, SPSS Inc.,
was used for statistical analysis.Results
In the period 1999–2001, 204 consecutive patients with
invasive breast carcinoma were included in the study. Two
years after surgery 23 of the 204 patients (11%) could not be
assessed. Fourteen patients belonged to the ALND group;
six patients died of metastatic disease; one patient had a
breast reconstruction and was excluded from assessment,
seven patients withdrew from the study because of other
reasons. Nine patients belonged to the SLNB group; one
patient had distant metastasis, one patient refused further
treatment and seven of them found the assessment protocol
bothersome and chose to withdraw from the study.
One hundred and eighty-one patients could be evaluated
after 2 years; 57 patients (32%) in the SLNB group and 124
patients (68%) in the ALND group. TNM classification,
receptor status and treatment characteristics of these
patients are presented in an earlier study.38
Substantial long-term treatment-related upper-limb mor-
bidity and increasing of disability was observed for the
whole study group (Table 1). Also significant changes were
found for QOL assessed with the EORTC QLQ-C30/QLQ-
BR23 (Table 2).
Several changes in upper-limb function (upper-limb
morbidity), ADL (perceived disability) and QOL between
before surgery and 2 years after treatment were significantly
Table 2








Physical functioning 91.3G11.1 K5.2G13.3 !0.001
Role functioning 92.4G16.2 K5.4G23.8 0.003
Emotional functioning 71.2G19.9 15.8G20.7 !0.001
Cognitive functioning 87.4G15.5 K1.1G30.5 0.624
Social functioning 92.3G14.9 0G18.8 1.000
General health score QOL 80.4G18.0 K1.2G19.8 0.411
Symptom scales/items
Fatigue scale 16.4G20.2 4.2G17.5 0.002
Nausea and vomiting scale 3.0G11.1 1.7G16.1 0.166
Pain scale 8.8G17.5 6.1G21.4 !0.001
Dyspnoea 5.8G15.4 3.7G18.4 0.007
Insomnia (sleeplessness) 23.7G27.3 K4.1G29.4 0.063
Appetite loss 7.5G16.4 K2.1G20.1 0.173
Constipation 2.6G11.9 2.4G15.4 0.037
Diarrhea 4.1G12.1 K1.5G12.6 0.117
Financial difficulties 1.7G7.3 4.2G20.5 0.006
QLQ-BR23 (breast cancer module)
Side-effects 8.0G8.4 4.8G13.2 !0.001
Hair loss (only three
patients)
22.2G38.5 22.2G38.5 0.423
Body image 94.7G10.6 K3.2G17.1 0.014
Future perspective 59.7G25.1 12.7G28.2 !0.001
Sexual functioning (nZ137) 22.6G20.1 1.2G19.3 0.496
Sexual satisfaction (nZ57) 56.8G22.1 K4.9G27.0 0.185
Arm symptoms 4.9G10.2 8.8G19.4 !0.001
Breast symptoms 10.9G14.2 1.3G18.1 0.334
EORTC QLQ, European organization on research and treatment of cancer
quality of life questionnaire.35
Table 3
Change of upper limb function, disability and QOL in the SLNB group and














Numbness (n)a 10 (18%) 104 (84%)* 94 !0.001
Abduction (8) K5.5G21.0 K21.0G33.5* 15.5 !0.001
Abduction/exter-
nal rotation (8)
K3.5G8.0* K7.2G13.7* 3.7 0.025
Grip strength
(Nm)
K17.2G48.2* K41.3G51.7* 24.1 0.004
Volume arm (ml) K2G142.5 182G255.6* 184 !0.0001




K0.9G10.6 K7.3G13.9* 6.4 0.001
Role functioning K0.3G21.7 K7.8G24.4* 7.5 0.041
Pain 0.6G18.4 8.7G22.4* 8.1 0.012
Insomnia (sleep-
lessness)
K11.3G27.9* K0.8G29.6 10.5 0.027
QLQ-BR23 (breast cancer module)
Arm symptoms 3.0G11.5 11.5G21.7* 8.5 0.001
Results of t-test for independent samples. Nm, Newton meter; cm, centimetre;
(8), degree; *, significant changes between before and after surgery (P!.05).
GARS, the Groningen activity restriction scale;33,34 EORTC QLQ, European
organization on research and treatment of cancer quality of life questionnaire.35
a No standard deviations were given because it concerns a dichotomous
variable.
J.S. Rietman et al. / EJSO 32 (2006) 148–152150different between the SLNB group and the ALND group in
favour of the first (Table 3).
Multivariate linear regression analysis to predict the
mean change in upper-limb function, ADL and QOL
between before treatment and 2 years after treatment for
independent variables: age, axillary surgery, breast surgery,
radiation breast, radiation axilla and chemotherapy was
performed. ALND was a significant factor in the prediction
in the majority of mean changes in the performed
assessments of upper-limb function (abduction, grip
strength, arm volume), ADL (SDQ, GARS) and QOL
(physical functioning, pain, sleeplessness, diarrhea, arm
symptoms). Radiation of the axilla was significant in four
analyses: forward flexion, abduction, abduction/external
rotation and arm volume. Mastectomy was significant
associated with a lower body image (details not shown).
Discussion
Significant treatment related upper limb morbidity,
associated ADL disabilities and decreased QOL exist 2
years after SLNB or ALND. Treatment related upper limb
morbidity, perceived disabilities in ADL and worsening of
QOL 2 years after surgery is significantly less after SLNB
compared to ALND. In the assessment of changes in upperlimb function, ADL and QOL, ALND is the most frequent
found predictor of deterioration. Additional radiation on the
axilla predicts a further decrease in shoulder ROM and arm
oedema.
This outcome confirms results of previous studies
suggesting that SLNB is associated with less treatment
related upper-limb morbidity although these are no long-
term comparative studies.12–19,21,37,38 This is the first
prospective study comparing SLNB and ALND with pre-
and long-term post-surgical assessments of upper limb
function, ADL and QOL. In a recent systematic review and
two previous studies we emphasized the importance of the
baseline assessment and the use of reliable and validated
assessment instruments.6,37,38
The perceived disabilities in ADL assessed in this study
with the SDQ and GARS were significant but relatively
mild. Concerning QOL for the whole study group a
significant decrease was found over the 2 years for physical
and role functioning and body image whereas emotional
functioning and future perspective showed significant
increase over this period (Table 2). The improvement of
emotional functioning and future perspective can be
explained by the fact that the first assessment took place
1 day before surgery. Obviously at this time patients were
nervous and stressed and also uncertain about their future
perspective.21 Two years later these aspects were highly
improved.
Some scores on symptom scales increased significantly
such as fatigue, pain, dyspnoe, constipation, side-effects of
J.S. Rietman et al. / EJSO 32 (2006) 148–152 151systemic therapies and arm problems (Table 2). These
outcomes correspond with results found in earlier studies
done on breast cancer treatment and QOL.6–8,21 Comparing
SLNB and ALNB significantly differences in mean change
over the 2 years were found for physical and role
functioning and also for symptom items such as pain,
insomnia (sleeplessness) and arm symptoms in favour for
the SLNB group (Table 3).
The interpretation of the scores on the EORTC QLQ-C30
and QLQ-BR23 in relation to clinical relevance needs some
discussion. King did a review on the interpretation of scores
from the EORTC QLQ-C30 and stated that the smallest
clinically important difference may vary with clinical
context.41 All the statistically significant differences found
in our study within and between the groups could be
interpretated as relatively small clinically important
differences except the improvement of emotional function-
ing which could be interpretated as a very large clinically
important difference.41
Multivariate linear regression analysis to predict mean
change in upper-limb function, ADL and QOL between
before and 2 years after surgery showed that radiation on the
axilla is a significant factor in the prediction of impaired
ROM and increase of arm volume. This finding is a
conformation of results of some other studies and may be
explained by radiation induced subcutaneous fibrosis
affecting the ROM and lymph drainage.6,8,42,43 ALND as
predictor of upper limb morbidity was observed for
abduction, grip strength, arm volume, ADL and some
scales of the QLQ-C30 and QLQ-BR23. This result
confirms results of other studies in which the extent of
axillary treatment was found to be related to late
morbidity.6,19,20,42 Although the comparison between
mastectomy and breast conserving surgery was not subject
of this study we found that mastectomy predicts a part of the
decrease in body image. A lower body image in mastectomy
patients was earlier described.44Acknowledgements
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